Drugs / Matrix-M1 Adjuvant
Matrix-M1 Adjuvant
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT06320535 | Mar 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05385510 | Jan 2023 → Sep 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT05135273 | Oct 2021 → Feb 2023 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04318002 | Jan 2021 → Aug 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01669512 | Aug 2012 → Dec 2014 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01444482 | May → Nov 2011 | influenza | Isconova AB | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07779408 | Aug 2026 → Feb 2028 expected | influenza | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03896724 | May 2019 → Jul 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT05380388 | Jan → Dec 2027 expected | Plasmodium vivax malaria | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07074665 | Feb → Apr 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT05252845 | Jan → Jun 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT03947190 | Aug 2022 → Feb 2023 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04533399 | Aug 2020 → Dec 2021 | COVID-19 | Novavax | Completed | Met primary |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04704830 | Apr 2021 → Mar 2023 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | Met primary |
| Comparator or background therapy16 trials | ||||||
| Phase 0 | NCT05385471 Background | Jan 2023 → Mar 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05400746 Background | Nov 2022 → Oct 2023 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06958198 Background | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT05913973 Background | Aug 2023 → Nov 2025 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05357560 Background | Jul 2023 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT06141057 Background | Jun 2023 → Jul 2025 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04271306 Background | May 2021 → Feb 2024 | Plasmodium falciparum malaria | University of Oxford | Terminated | No outcome recorded |
| Phase 1/2 | NCT05978037 Comparator | Aug 2023 → Apr 2026 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT05790889 Background | Apr 2023 → May 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Recruiting | Mixed |
| Phase 1/2 | NCT03970993 Background | Jun 2019 → Aug 2021 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT07183371 Background | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06080243 Comparator | Mar 2025 → Sep 2027 expected | — | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03026348 Comparator | Jan → Apr 2017 | respiratory syncytial virus infectious disease | Novavax | Completed | No outcome recorded |
| Phase 3 | NCT06578572 Background | May → Dec 2024 overdue | malaria | London School of Hygiene and Tropical Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT07194668 Comparator | Apr → Dec 2026 expected | Plasmodium falciparum malaria, vaccinia | University of Oxford | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06068530 Comparator | Feb 2025 → Feb 2028 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2025-07-24 | Novavax | Results Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study novavax.com ↗
Results showed that a single dose administered by either IN or IM routes induced neutralizing antibody responses (IN: 1:54; IM: 1:1,160), at or above the 1:40 titer generally considered to be a protective antibody response. |
| 2024-02-02 | Novavax | Results R21/Matrix-M™ Malaria Vaccine Phase 3 Trial Results Published in The Lancet novavax.com ↗
Today, peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M™ malaria vaccine were published in The Lancet . |
| 2023-12-21 | Novavax | Regulatory R21/Matrix-M™ Malaria Vaccine Granted Prequalification by World Health Organization novavax.com ↗
The World Health Organization (WHO) announced today that it has prequalified the R21/Matrix-M™ malaria vaccine to prevent malaria disease in children caused by the P. falciparum parasite in endemic areas. |
| 2023-10-02 | Novavax | Regulatory R21/Matrix-M™ Malaria Vaccine with Novavax’s Adjuvant Technology Receives WHO Recommendation novavax.com ↗
Today, the World Health Organization (WHO) announced its recommendation of the R21/Matrix-M™ malaria vaccine to prevent malaria in children following advice from its Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG). |
| 2023-07-24 | Novavax | Regulatory R21/Matrix-M™ Malaria Vaccine Leveraging Novavax’s Adjuvant Technology Gains Additional Authorization novavax.com ↗
The Institut de Recherche en Sciences de la Santé (IRSS) announced today that the R21/Matrix-M™ malaria vaccine has been approved for use in children by Burkina Faso’s regulatory agency, Agence Nationale de la Regulation Pharmaceutique (ANRP). |
| 2022-02-14 | Novavax | Regulatory Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland novavax.com ↗
today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorization (CMA) of NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant, for use in adults. |
| 2022-02-10 | Novavax | Results Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial novavax.com ↗
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, achieved its primary effectiveness endpoint in the pediatric expansion of its PREVENT-19 pivotal Phase 3 trial and demonstrated 80% efficacy overall at a time when the Delta variant was the predominant circulating strain in the U.S. |
| 2021-12-22 | Novavax | Results Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies novavax.com ↗
New results demonstrate broad cross-reactivity against Omicron and other circulating variants from a primary 2-dose regimen, with responses that increased following a third dose at six months. |
| 2021-12-15 | Novavax | Results Novavax Statement on PREVENT-19 Phase 3 Clinical Trial Results Publication in the New England Journal of Medicine novavax.com ↗
The trial demonstrated 100% protection against moderate and severe disease, 93.2% efficacy against the predominantly circulating variants of concern and variants of interest, and 90.4% efficacy against COVID-19 of any severity during the time period evaluated. |
| 2021-12-02 | Novavax | Results Novavax Statement on Omicron Variant Response novavax.com ↗
Matrix-M adjuvant was shown to increase and broaden immune response , with a demonstrated ability to stimulate high levels of neutralizing antibodies and T-cell responses. |
| 2021-11-17 | Novavax | Regulatory Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines novavax.com ↗
today announced that the Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. |
| 2021-11-03 | Novavax | Regulatory Novavax Files COVID-19 Vaccine for Provisional Approval in New Zealand novavax.com ↗
Novavax has now completed the submission to Medsafe of all modules required for the regulatory evaluation of NVX-CoV2373, a recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M™ adjuvant. |
| 2021-11-01 | Novavax | Regulatory Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia novavax.com ↗
Badan POM has issued Emergency Use Authorization (EUA) for Covovax /Recombinant Spike Protein of SARS-CoV-2 Virus 5 mcg to induce immunity against SARS-CoV-2 to prevent COVID-19 for adults 18 years old and above. |
All press releases naming this drug 14 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matrix-M1 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03026348 ↗ |
| Known as | Matrix M | “A mixture of R21/Matrix M at a dose of 5 μg (for children up to 14 years of age) or 10 μg ( for individuals ≥ 15 years old) with 50 μg of Matrix-M will be administered monthly...” NCT06578572 ↗21“A Phase 1/2, Parallel, Observer-blind Study to Assess the Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in...” NCT07779408 ↗ “This is given with an adjuvant called "Matrix-M". This is a substance to improve the body's response to a vaccination.” NCT06141057 ↗ “Matrix M™ is a vaccine adjuvant, a compound used to improve the immune responses to vaccines.” NCT01669512 ↗ “R21/Matrix-M™, a leading Plasmodium falciparum malaria vaccine” NCT06320535 ↗ |
| Known as | PvRII/Matrix-M | “candidate malaria vaccine PvRII/Matrix-M” NCT05380388 ↗ |
| Known as | R21 | “R21 vaccinated volunteers receiving DVI sporozoites met the primary endpoint” PMID 41495411 ↗ Jan 2026 |
| Known as | R21/MatrixM | “R21/Matrix-M is a vaccine against P. falciparum malaria, which has WHO prequalification and policy recommendation in children over 5 months old in malaria endemic areas.” NCT07074665 ↗7“R21/MatrixM (MM) had a favourable safety profile and was well tolerated.” NCT05252845 ↗ |
| Known as | SARS-CoV-2 rS/Matrix-M1 Adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04533399 ↗ |
| Modality | Other / unclassified | “Matrix M™ is a vaccine adjuvant, a compound used to improve the immune responses to vaccines.” NCT01669512 ↗ |
| Route | Intramuscular | “Vaccines will be administrated intramuscularly in the upper arm.” NCT01444482 ↗ |